Although some small randomized trials have shown a trend towards an improved disease progression or overall survival when interferon was added to SSA as first line treatment, this benefit was not consistently observed in all trials or did not reach statistical significance [ 3 , 4 ].
← all excerpts
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
1
—
—